Evidence map›Paper›PMID 35332148›Full record

ReviewNature reviews. Disease primers2022

Tobacco and nicotine use.

Bernard Le Foll, Megan E Piper, Christie D Fowler, Serena Tonstad, Laura Bierut, Lin Lu, Prabhat Jha, Wayne D Hall

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
153citing papers in PubMed, 7 pooled it
23.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

153 citing papers in PubMed, 7 syntheses or guidelines pooled it, 281 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Article
  14. Rapid and reliable computational markers of decision-making for predicting daily smoking behavior and smoking cessation treatment outcomes.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  15. The role of the gut microbiome in nicotine withdrawal and dependence.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

93 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 5 countries.

Bernard Le FollTranslational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada. bernard.lefoll@camh.ca.
Megan E PiperDepartment of Medicine, University of Wisconsin, Madison, WI, USA.
Christie D FowlerDepartment of Neurobiology and Behaviour, University of California Irvine, Irvine, CA, USA.
Serena TonstadSection for Preventive Cardiology, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway.
Laura BierutDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Lin LuInstitute of Mental Health, Peking University Sixth Hospital, Peking University, Beijing, China.ORCID 0000-0003-0742-9072
Prabhat JhaCentre for Global Health Research, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada.
Wayne D HallNational Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Queensland, Australia.
Centre for Addiction and Mental Health · CAOslo University Hospital · NOPeking University · CNThe University of Queensland · AUUniversity of California, Irvine · USUniversity of Toronto · CAUniversity of Wisconsin–Madison · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tobacco smoking is a major determinant of preventable morbidity and mortality worldwide. More than a billion people smoke, and without major increases in cessation, at least half will die prematurely from tobacco-related complications. In addition, people who smoke have a significant reduction in their quality of life. Neurobiological findings have identified the mechanisms by which nicotine in tobacco affects the brain reward system and causes addiction. These brain changes contribute to the maintenance of nicotine or tobacco use despite knowledge of its negative consequences, a hallmark of addiction. Effective approaches to screen, prevent and treat tobacco use can be widely implemented to limit tobacco's effect on individuals and society. The effectiveness of psychosocial and pharmacological interventions in helping people quit smoking has been demonstrated. As the majority of people who smoke ultimately relapse, it is important to enhance the reach of available interventions and to continue to develop novel interventions. These efforts associated with innovative policy regulations (aimed at reducing nicotine content or eliminating tobacco products) have the potential to reduce the prevalence of tobacco and nicotine use and their enormous adverse impact on population health.

Indexed as

Smoking CessationTobacco ProductsHumansNicotineQuality of LifeTobacco UseTobacco Use Cessation DevicesNicotine

Identifiers

PMID35332148
OpenAlexW4220829235

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.